Our Lm Technology™ utilizes the efficiency of the entire immune system by teaching it to recognize the tumor as a threat, and by weakening the tumor’s defenses. Once educated by Lm Technology™, the immune system—specifically, its killer T cells—are enabled to do their job and work to destroy the cancer.
Advaxis and Amgen are collaborating to develop ADXS-NEO, an immunotherapy designed to stimulate a targeted immune response by using a patient's own tumor neoepitopes and our Lm Technology™. Advaxis is a proud member of The TESLA Consortium. Learn More.